Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Trevaclyn er større end risiciene ved behandling af dyslipidæmi, især hos patienter med kombineret blandet dyslipidæmi og patienter med primær hyperkolesterolæmi.
The Committee for Medicinal Products for Human Use (CHMP) decided that Trevaclyn’ s benefits are greater than its risks for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia and in patients with primary hypercholesterolaemia.